Plain-English translation of NCT06340750 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage study testing a new treatment called , which uses your own immune cells that have been specially modified in a laboratory to target and calm down the part of your immune system that causes lupus. The goal is to learn whether this treatment is safe and how well it works for people whose lupus hasn't improved with standard medications.
Lupus is an autoimmune disease that can be very difficult to control, and some people don't respond well to current treatments or can't tolerate them because of side effects. This medication offers a new approach by directly targeting a key driver of lupus activity, potentially offering hope to people who haven't found relief through other options.
You likely qualify if…
You likely don't qualify if…
If you join this study, your own immune cells will be collected from your blood and sent to a laboratory where they will be modified to recognize and attack a specific target involved in lupus. You will then receive these modified cells back as an infusion. The study includes careful monitoring with visits to check your safety and how you're responding, with at least a 14-day observation period between when the first few patients receive their treatment to ensure safety before enrolling the next participants.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
United States
Phase
Safety & dosing
Sponsor
Luminary Therapeutics
Collaborators
Nationwide Children's Hospital
Enrollment target
~18 participants
Started
April 2025
Primary completion
April 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 65 Years
Last updated on clinicaltrials.gov in June 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Matthew A Spear, MD
Nationwide Children's Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.